Dosage ; 10U bolus dose followed by a second 10U bolus dose 30 minutes later (double bolus)
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Rapilysin | Roche | Roche Products | 10IU | 2 | Injection | per ml | KES 93,312 |
| Reteplase More info | |
|---|---|
| Mode Of Action | Recombinant plasminogen activators catalyze the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades fibrin, which is the main component of the matrix of thrombi, thereby exerting its thrombolytic action. |
| Drug Indication | Thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of a myocardial infarction symptoms. |
| Precautions | Patients to be carefully evaluated before treatment. |
| Side Effects | Haemorrhage; cardiovascular events such as recurrent ischaemia/angina, hypotension, heart failure/pulmonary oedema, arrhythmias; mitral regurgitation. |
| Dosage | 10U bolus dose followed by a second 10U bolus dose 30 minutes later (double bolus). Each bolus is administered as a slow intravenous injection within 2 minutes. Heparin and acetylsalicylic acid should be administered before and following its administration to reduce the risk of rethrombosis. |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Fibrinolytics |